Gilead Sciences Reports Phase 3 PURPOSE 2 Results for Lenacapavir in HIV Prevention

Gilead Sciences today announced results from the Phase 3 PURPOSE 2 trial evaluating twice-yearly subcutaneous lenacapavir for HIV prevention in cisgender men, transgender women, transgender men, and gender non-binary individuals. The trial demonstrated 96% efficacy of lenacapavir in preventing HIV infection compared to background incidence. These results support regulatory submissions for lenacapavir as a long-acting HIV prevention option.